Samarth Kulkarni Sells 18,360 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, December 2nd, Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $55.10, for a total value of $826,500.00.

CRISPR Therapeutics Stock Down 5.0 %

NASDAQ CRSP opened at $47.91 on Friday. The stock’s 50-day simple moving average is $42.25 and its two-hundred day simple moving average is $46.06. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $91.10. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of -10.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities analysts expect that CRISPR Therapeutics AG will post -5.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CRSP shares. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Stifel Nicolaus dropped their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Barclays increased their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Finally, TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $74.40.

Institutional Trading of CRISPR Therapeutics

Large investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new stake in CRISPR Therapeutics in the third quarter worth about $40,000. Darwin Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $43,000. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics in the 4th quarter valued at approximately $39,000. Western Pacific Wealth Management LP lifted its position in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares in the last quarter. Finally, Eastern Bank bought a new position in CRISPR Therapeutics in the 3rd quarter valued at approximately $70,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.